story of the week
HER2-Enriched Subtype as a Predictor of Pathological Complete Response Following Trastuzumab and Lapatinib Without Chemotherapy in Early-Stage HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
HER2-Enriched Subtype as a Predictor of Pathological Complete Response Following Trastuzumab and Lapatinib Without Chemotherapy in Early-Stage HER2-Positive Breast Cancer (PAMELA): An Open-Label, Single-Group, Multicentre, Phase 2 Trial
Lancet Oncol 2017 Feb 23;[EPub Ahead of Print], A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, M Vidal, S Pernas, R López, M Muñoz, P Nuciforo, S Morales, M Oliveira, L de la Peña, A Peláez, A PratFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.